Immunomic Therapeutics

117 articles about Immunomic Therapeutics

• Immunomic Therapeutics Announces Presentation on Manufacturing Cell Therapies at Supply Chain and Logistics for Cell Therapy Summit 2023

  3/6/2023

  Immunomic Therapeutics, Inc. announced today that it will present at the Supply Chain and Logistics for Cell Therapy Summit, March 7-9 in Boston, MAs.

• Immunomic Therapeutics to Present at Biotech Showcase 2023

  1/4/2023

  Immunomic Therapeutics, Inc. announced today that Dr. William Hearl, Chief Executive Officer, will give a presentation entitled, “Dynamic Activation of the Immune System Using UNITE ® Technology, Nucleic Acid-Based Cell Therapies for Immuno-Oncology,” at Biotech Showcase 2023, being held January 9-11, 2023 in San Francisco.

• Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma

  11/8/2022

  Immunomic Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the ITI-3000 program for the treatment of patients with Merkel cell carcinoma.

• Immunomic Therapeutics Announces Presentation on Nucleic Acid-Based UNITE® Vaccine Platform at Vaccines Summit 2022

  10/10/2022

  Immunomic Therapeutics, Inc. announced today that it will present at the Vaccines Summit 2022 at the Sheraton Reston Hotel in Reston, VA on October 11-13.

• Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs

  9/6/2022

  Immunomic Therapeutics, Inc., a privately-held clinical-stage biotechnology company pioneering the study of LAMP -mediated nucleic acid-based immunotherapy, announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs.

• Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma

  7/20/2022

  Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced dosing of the first patient in the company’s Phase 1 study evaluating ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with Merkel cell carcinoma.

• Immunomic Therapeutics Appoints Vice President, Cell Therapy

  6/7/2022

  Immunomic Therapeutics, Inc., a privately-held clinical-stage biotechnology company pioneering the study of LAMP -mediated nucleic acid-based immunotherapy announced the appointment of Brian Stamper to Vice President, Cell Therapy Operations.

• Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2022

  4/14/2022

  Immunomic Therapeutics, Inc., a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced that the company will be presenting at the World Vaccine Congress in Washington, DC being held April 18-21, 2022.

• Immunomic Therapeutics Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022

  4/8/2022

  Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that the data from two posters are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 held in New Orleans, Louisiana, from April 8-13.

• Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

  3/31/2022

  Immunomic Therapeutics, Inc. announced today that the company will be presenting two posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held in New Orleans, Louisiana, from April 8-13.

• Immunomic Therapeutics to present at the BIO CEO & Investor Conference 2022

  2/11/2022

  Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting at the upcoming 2022 BIO CEO & Investor Conference.

• Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma

  2/7/2022

  Immunomic Therapeutics, Inc. today announced its first Phase 1 clinical study evaluating ITI-3000 in patients with Merkel cell carcinoma (MCC).

• Immunomic Therapeutics’ CBO to present at the 14th Annual Biotech Showcase Event

  1/6/2022

  Immunomic Therapeutics, Inc. announced that the company will present at the 14th Annual Biotech Showcase Event, January 10-12 and January 17-19, virtually.

• Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the Treatment of Newly-Diagnosed Glioblastoma Patients

  11/30/2021

  Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced the opening of a new clinical study in collaboration with Dr. Duane Mitchell at the University of Florida.

• Immunomic Therapeutics Announces Collaboration With iOncologi

  11/23/2021

  Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnology company focused on advancing its proprietary nucleic acid immunotherapy platform, announced today an exclusive option to license or acquire a series of innovative technologies in the immuno-oncology space from iOncologi, Inc., (“iOi”).

• Immunomic Therapeutics Presents Clinical Data From ATTAC Studies in GBM at the 2021 Society for Neurology (SNO) Annual Meeting

  11/18/2021

  Immunomic Therapeutics, Inc. (‘ITI’), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that Kristen Batich, MD, Ph.D. and a team from Duke University School of Medicine will present clinical data at the 2021 Society for Neurology (SNO) Annual Meeting.

• Immunomic Therapeutics Expands Board of Directors with Appointments of Two New Members

  7/27/2021

  Immunomic Therapeutics, Inc., (“ITI”), announced today that it has appointed Steve Sang Young Park and Robert V. Ahlgren as new members to its Board of Directors, expanding the board to twelve members.

• Immunomic Therapeutics Strengthens Leadership Team with Appointment of Robert Newman as Chief Business Officer

  7/19/2021

  Immunomic Therapeutics, Inc. announced today that it has appointed Robert Newman as Chief Business Officer.

• 

  Global Roundup: uniQure Snaps Up Corlieve, Avacta Group's Deal and More

  6/24/2021

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2021

  4/27/2021

  Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually May 4-6, 2021. CEO and Co-Founder Bill Hearl, Ph.D., will present a talk titled, “Adaptive T-cell immunotherapy for newly diagnosed glioblastoma: Using targeted antigen presentation to enhance immune responses,” at 15:00 on May 4, 2021.